Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

Provided By PR Newswire

Last update: Aug 23, 2022

PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients

BETHESDA, Md., Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, today announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for adult patients, such as DCVax^®-L.